trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

Indinavir functions as an HIV protease inhibitor.

the verdict
SUPPORTED
the evidence backs this
Recorded sources
7 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that Indinavir functions as an HIV protease inhibitor?

Yes. Indinavir is well-established in the scientific literature as a potent HIV protease inhibitor used in combination antiretroviral therapies.

Verdict: SUPPORTED · 7 sources for, 0 against · Last checked

The analysis

The retrieved papers consistently refer to and evaluate indinavir as an HIV protease inhibitor used in the treatment of HIV-1 infection. There is no evidence refuting this pharmacological classification.

Evidence for · 7
Low Plasma Concentrations of Indinavir are Related to Virological Treatment Failure in HIV-1-Infected Patients on Indinavir-Containing Triple Therapy
1998
Evaluates indinavir as a protease inhibitor in HIV-1 triple therapy regimens.
Get citation
Burger, D. M., Hoetelmans, R. M., Hugen, P. W., Mulder, J. W., Meenhorst, P. L., Koopmans, P. P., Brinkman, K., Keuter, M., Dolmans, W., & Hekster, Y. A. (1998). Low Plasma Concentrations of Indinavir are Related to Virological Treatment Failure in HIV-1-Infected Patients on Indinavir-Containing Triple Therapy. doi.org. https://doi.org/10.1177/135965359800300401

See more details
More for · 6
Trimethoprim-Sulfamethoxazole (Tmp/Smx) Potentiates Indinavir Nephrotoxicity
2002
Discusses indinavir as a widely prescribed protease inhibitor in the treatment of HIV infection.
Get citation
Araujo, M. d. & Seguro, A. C. (2002). Trimethoprim-Sulfamethoxazole (Tmp/Smx) Potentiates Indinavir Nephrotoxicity. doi.org. https://doi.org/10.1177/135965350200700307

Efficacy and Safety of Ritonavir/Indinavir 100/400 Mg Twice Daily in Combination with Two Nucleoside Analogues in Antiretroviral Treatment-Naive HIV-Infected Individuals
2003
Assesses indinavir/ritonavir as part of antiretroviral treatment for HIV-infected individuals.
Get citation
Duvivier, C., Astriti, M., Marcelin, A., Ghosn, J., Ait-Mohand, H., Schneider, L., Agher, R., Bricaire, F., Costagliola, D., Calvez, V., Peytavin, G., & Katlama, C. (2003). Efficacy and Safety of Ritonavir/Indinavir 100/400 Mg Twice Daily in Combination with Two Nucleoside Analogues in Antiretroviral Treatment-Naive HIV-Infected Individuals. doi.org. https://doi.org/10.1177/135965350300800607

Efficacy and Safety of Indinavir/Ritonavir 400/100 mg Twice Daily plus Two Nucleoside Analogues in Treatment-Naive HIV-1-Infected Patients with CD4 <sup>+</sup> T-cell Counts <200 cells/mm <sup>3</sup> : 96-Week Outcomes
2005
Investigates the efficacy and safety of an indinavir-containing regimen in HIV-1-infected patients.
Get citation
Mootsikapun, P., Chetchotisakd, P., Anunnatsiri, S., & Boonyaprawit, P. (2005). Efficacy and Safety of Indinavir/Ritonavir 400/100 mg Twice Daily plus Two Nucleoside Analogues in Treatment-Naive HIV-1-Infected Patients with CD4
                    <sup>+</sup>
                    T-cell Counts <200 cells/mm
                    <sup>3</sup>
                    : 96-Week Outcomes. doi.org. https://doi.org/10.1177/135965350501000806

Vasodilator Agents Protect against Indinavir Nephrotoxicity
2003
Notes that indinavir is a protease inhibitor widely used in AIDS treatment.
Get citation
Araujo, M. d. & Seguro, A. C. (2003). Vasodilator Agents Protect against Indinavir Nephrotoxicity. doi.org. https://doi.org/10.1177/135965350300800405

Advancements in development of novel class of HIV protease inhibitors.
2026
Confirms that protease inhibitors, including indinavir, are significant agents in HIV treatment targeting the viral protease enzyme.
Get citation
WG, G., GZ, Y., & YP, Z. (2026). Advancements in development of novel class of HIV protease inhibitors.. doi.org. https://doi.org/10.1080/07853890.2026.2617730

Repurposing HIV Protease Inhibitors against West Nile Virus: Insights from Molecular Docking and Molecular Dynamics Simulations.
2026
Evaluates the repurposing of HIV protease inhibitors, including indinavir, against other viral proteases.
Get citation
RD, D. S., G, C., & WB, C. (2026). Repurposing HIV Protease Inhibitors against West Nile Virus: Insights from Molecular Docking and Molecular Dynamics Simulations.. doi.org. https://doi.org/10.1021/acsphyschemau.6c00043

What does the evidence say?

The retrieved papers consistently refer to and evaluate indinavir as an HIV protease inhibitor used in the treatment of HIV-1 infection. There is no evidence refuting this pharmacological classification.

Receipt History
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

See the evidence timeline

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work